Published in Stroke on September 18, 2014
Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clin J Am Soc Nephrol (2017) 0.75
Atherogenic indices in stroke patients: A retrospective study. Iran J Neurol (2017) 0.75
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med (1999) 9.83
Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med (2014) 9.25
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA (2005) 5.74
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014) 4.14
Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA (2008) 3.10
Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation (2002) 2.95
Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke (2007) 2.63
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet (2003) 2.37
Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol (2009) 2.33
Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med (2001) 2.22
Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation (2008) 2.19
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation (2001) 2.11
Lipid profile components and risk of ischemic stroke: the Northern Manhattan Study (NOMAS). Arch Neurol (2009) 1.74
Secondary preventive medication persistence and adherence 1 year after stroke. Neurology (2011) 1.62
Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke (2003) 1.58
Statin treatment and adherence to national cholesterol guidelines after ischemic stroke. Neurology (2006) 1.57
The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J (2009) 1.36
The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J (1998) 1.26
A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. Ann Epidemiol (2005) 1.17
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: The Suita study. Atherosclerosis (2008) 1.11
Cholesterol and the risk of ischemic stroke. Stroke (2003) 1.11
Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation (2001) 1.05
Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology (2006) 1.05
Total and high-density lipoprotein cholesterol and stroke risk. Stroke (2012) 1.00
High-density lipoprotein and cardiovascular risk. Circulation (2004) 0.99
Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol (2010) 0.96
Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke (2014) 0.95
Non-high-density lipoprotein cholesterol on the risks of stroke: a result from the Kailuan study. PLoS One (2013) 0.90
The metabolic syndrome: a practical guide to origins and treatment: Part II. Circulation (2003) 0.89
Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events - the JALS-ECC -. Circ J (2010) 0.88
Association of serum lipid indices with large artery atherosclerotic stroke. Neurology (2007) 0.87
High levels of apolipoprotein B/AI ratio are associated with intracranial atherosclerotic stenosis. Stroke (2011) 0.85
Low HDL cholesterol is associated with the risk of stroke in elderly diabetic individuals: changes in the risk for atherosclerotic diseases at various ages. Diabetes Care (2009) 0.83
Atherogenic dyslipidemia in patients with transient ischemic attack. Stroke (2011) 0.83
Apolipoproteins B and AI and the risk of ischemic cerebrovascular events in patients with pre-existing atherothrombotic disease. J Neurol Sci (2008) 0.82
Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab (2010) 0.82
Achieving target cholesterol goals after stroke: is in-hospital statin initiation the key? Arch Neurol (2006) 0.79